Brenus Pharma is advancing an off-the-shelf platform in immuno-oncology that mimics tumor protein expression to make tumors visible to the immune system. Its lead clinical-stage asset is STC-1010 (NCT06934538), targeting MSS metastatic colorectal cancer, and recent execution across clinical, regulatory and business development milestones has been highlighted by the company. Brenus positions its technology for multi-asset expansion and plans to use new capital to complete the Phase I program for STC-1010 and to advance its next drug candidate. The company has raised a total of €38 million since inception following the €11 million Series A extension. The firm announced the financing from Lyon, France and continues engaging both existing and new international investors to support its development plans.

Total raised

$38M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2026